Mr. Ilan Sobel reports

BIOHARVEST SCIENCES TO HOST CORPORATE UPDATE DISCUSSING LAUNCH OF CDMO BUSINESS UNIT ON MARCH 13 AT 2:30 P.M. EASTERN TIME

Bioharvest Sciences Inc. will host a corporate update webinar on Wednesday, March 13, to discuss the company's contract development and manufacturing organization (CDMO) business unit.

The new CDMO business unit allows pharmaceutical, cosmeceutical, nutraceutical and nutrition industry leaders the opportunity to utilize Bioharvest's botanical synthesis process technology through a business model which includes both development and long-term manufacturing contracts. The proprietary botanical synthesis process provides these industry leaders, who are searching for the next generation of therapeutic molecules, with capabilities to source new patentable plant-based molecules which offer unique advantages such as lower development and manufacturing costs, faster development speed (15 to 24 months), manufacturing consistency and enhanced safety.

Chief executive officer Ilan Sobel and chairman Zaki Rakib will host the call at 2:30 p.m. Eastern Time on Wednesday, March 13, 2024, with a formal presentation to discuss the launch of the CDMO business unit, provide a corporate update and conclude with a question-and-answer session. To participate, please use the information included herein.

CDMO corporate update webinar

Date:  Wednesday, March 13, 2024

Time:  2:30 p.m. Eastern Time

Investors and media are advised to join at least five minutes before the start of the event to ensure timely participation.

Chairman Zaki Rakib stated: "We architected this new CDMO services division to complement our product division, which we believe will allow us to more efficiently monetize our botanical synthesis technology platform. The new business unit has the potential to turn plants into predictable and reliable sources of therapeutic molecules -- not only because we will be developing them alongside industry customers, but also because each new molecular project will allow us to expand our IP library and predictive abilities more efficiently. I look forward to discussing our progress with our shareholders, as this is a truly momentous step in Bioharvest's growth trajectory."

CEO Ilan Sobel concluded: "Our initial two CDMO customers serve as strong validation of the industry need for solutions such as those offered by our botanical synthesis process. As we move ahead, we will continue to aggressively push for additional agreements in the quarters to come. I would like to thank our whole science team -- including chairman Dr. Zaki Rakib, CTO Dr. Yochi Hagai and VP of R&D Dr. Malkit Azahi -- for making this possible. Their experience, paired with the success of our own red grape cell complex molecule product, has proven instrumental in building the credibility needed to secure these initial customers."

About Bioharvest Sciences Inc.

Bioharvest Sciences is a fast-growing biotech firm listed on the Canadian Securities Exchange. Bioharvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. Bioharvest is currently focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions, within two major business verticals -- nutraceutical health and wellness products such as dietary supplements, and development of plant cell-based active pharmaceutical ingredients (APIs) that focus on specific medical indications.

We seek Safe Harbor.